For most patients with HER2-positive early breast cancer, standard treatment should remain the same, according to new findings. Most women with this type of breast cancer will receive the drug trastuzumab, along with other therapies and surgery.
Sure, ad-blocking software does a great job at blocking ads, but it also blocks useful features of our website. For the best site experience please disable your AdBlocker.
